Retrieve available abstracts of 26 articles: HTML format
Single Articles
July 2025
KIM YS, Nabet BY, Cortez BN, Sun NY, et al NOTCH1 reverses immune suppression in small cell lung cancer through reactivation
of STING.
J Clin Invest. 2025 Jul 8:e185423. doi: 10.1172/JCI185423. PubMedAbstract available
June 2025
DESAI SS, Salahuddin S, Yusuf R, Ranjan K, et al Tumor microenvironment of non-small cell lung cancer impairs immune cell function
among people with HIV.
J Clin Invest. 2025 Jun 3:e177310. doi: 10.1172/JCI177310. PubMedAbstract available
LEE S, Park J, Cho S, Kim EJ, et al Hyaluronan network remodeling by ZEB1 and ITIH2 enhances the motility and
invasiveness of cancer cells.
J Clin Invest. 2025;135:e180570. PubMedAbstract available
May 2025
APPADURAI MI, Chaudhary S, Shah A, Natarajan G, et al ST6GalNAc-I regulates tumor cell sialylation via NECTIN2/MUC5AC-mediated
immunosuppression and angiogenesis in non-small cell lung cancer.
J Clin Invest. 2025;135:e186863. PubMedAbstract available
April 2025
O'KEEFE S, Wang Q ACAT1 regulates tertiary lymphoid structures: A target for enhancing
immunotherapy in non-small cell lung cancer.
J Clin Invest. 2025;135:e191094. PubMedAbstract available
WANG S, Guo H, Fukushima R, Terajima M, et al Lysyl hydroxylase 2 glucosylates collagen VI to drive lung cancer progression.
J Clin Invest. 2025;135:e189197. PubMedAbstract available
JIAO M, Guo Y, Zhang H, Wen H, et al ACAT1 regulates tertiary lymphoid structures and correlates with immunotherapy
response in non-small cell lung cancer.
J Clin Invest. 2025;135:e181517. PubMedAbstract available
March 2025
SHEN S, Zhang Q, Wang Y, Chen H, et al Targeting ubiquitin-independent proteasome with small molecule increases
susceptibility in pan-KRAS-mutant cancer models.
J Clin Invest. 2025;135:e185278. PubMedAbstract available
February 2025
YU F, Zheng S, Yu C, Gao S, et al KRAS Mutants Confer Platinum Resistance by Regulating ALKBH5 Post-translational
Modifications in Lung Cancer.
J Clin Invest. 2025 Feb 4:e185149. doi: 10.1172/JCI185149. PubMedAbstract available
December 2024
LI D, Geng K, Hao Y, Gu J, et al Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung
cancer models.
J Clin Invest. 2024 Dec 24:e174249. doi: 10.1172/JCI174249. PubMedAbstract available
October 2024
HUANG Q, Tian N, Zhang J, Song S, et al Nonclassical action of Ku70 promotes Treg-suppressive function through a
FOXP3-dependent mechanism in lung adenocarcinoma.
J Clin Invest. 2024;134:e178079. PubMedAbstract available
September 2024
REEVES MQ Mapping the transcriptional evolution of human metastatic breast cancer.
J Clin Invest. 2024;134:e183971. PubMedAbstract available
June 2024
PARDO L, Norman JC Targeting the secretory program of 3q-amplified lung cancers.
J Clin Invest. 2024;134:e181798. PubMedAbstract available
May 2024
MILLS GB, Labrie M Enhancing anticancer activity of macrophages through rational drug combinations.
J Clin Invest. 2024;134:e180512. PubMedAbstract available
April 2024
HAYASHI H, Chamoto K, Hatae R, Kurosaki T, et al Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and
response to PD-1 blockade.
J Clin Invest. 2024;134:e168318. PubMedAbstract available
TAN AC, Cook SL, Khasraw M Soluble immune-checkpoint factors: a potential immunotherapy biomarker.
J Clin Invest. 2024;134:e179352. PubMedAbstract available
March 2024
VACCARO K, Allen J, Whitfield TW, Maoz A, et al Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated
destruction.
J Clin Invest. 2024;134:e169315. PubMedAbstract available
CHEN Z, Vallega KA, Wang D, Quan Z, et al DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in
EGFR-mutant non-small cell lung cancer models.
J Clin Invest. 2024 Mar 7:e172716. doi: 10.1172/JCI172716. PubMedAbstract available
January 2024
PEYVANDI S, Bulliard M, Yilmaz A, Kauzlaric A, et al Tumor-educated Gr1+CD11b+ cells drive breast cancer metastasis via
OSM/IL6-JAK-induced cancer cell plasticity.
J Clin Invest. 2024 Jan 18:e166847. doi: 10.1172/JCI166847. PubMedAbstract available
GHANBAR MI, Suresh K Pulmonary toxicity of immune checkpoint immunotherapy.
J Clin Invest. 2024;134:e170503. PubMedAbstract available
December 2023
JING N, Zhang K, Chen X, Liu K, et al ADORA2A-driven proline synthesis triggers epigenetic reprogramming in
neuroendocrine prostate and lung cancers.
J Clin Invest. 2023;133:e168670. PubMedAbstract available
WANG S, Iyer R, Han X, Wei J, et al CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive
regulator for tumor immune evasion.
J Clin Invest. 2023;133:e167728. PubMedAbstract available
November 2023
MAKINEN N, Meyerson M Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung
cancer.
J Clin Invest. 2023;133:e174171. PubMedAbstract available
October 2023
LIU S, Saunders M, Mak TW Chemical carcinogens: implications for cancer treatment.
J Clin Invest. 2023;133:e174319. PubMedAbstract available
HUANG M, Xia Y, Li K, Shao F, et al Carcinogen exposure enhances cancer immunogenicity by blocking the development of
an immunosuppressive tumor microenvironment.
J Clin Invest. 2023;133:e166494. PubMedAbstract available
WANG T, Dong Y, Huang Z, Zhang G, et al Antioxidants stimulate BACH1-dependent tumor angiogenesis.
J Clin Invest. 2023;133:e169671. PubMedAbstract available